RIPK1 and neurodegenerative disease: With ongoing advances of increasing number of RIPK1 inhibitors in human clinical studies for the treatment of many different human inflammatory and degenerative diseases, we expect that studies of RIPK1 in normal aging and aging-related diseases will continue to provide helpful guidance and new exciting directions.